​

Plus Therapeutics (PSTV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PSTV Stock Rating

Plus Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

PSTV Price Target Upside V Benchmarks

TypeNameUpside
StockPlus Therapeutics-
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.35$0.35$0.35
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25211--4
May, 2522---4
Apr, 2522---4
Mar, 2522---4
Feb, 2522---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 15, 2024H.C. WainwrightBuyBuyhold
Sep 03, 2024AscendiantBuyBuyhold

Financial Forecast

EPS Forecast

$-35 $-27 $-19 $-11 $-3 $5 Dec 20 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-31.67$-11.91$-4.24$-0.20----
Avg Forecast$-22.30$-11.06$-4.63$-1.94$-1.49$-1.51$-1.08$0.34
High Forecast$-15.65$-9.20$-4.19$-1.75$-1.44$-0.72$-0.06$0.37
Low Forecast$-27.44$-12.67$-5.07$-2.12$-1.53$-2.46$-1.97$0.30
Surprise %42.02%7.69%-8.42%-89.69%----

Revenue Forecast

$0 $16M $32M $48M $64M $80M Dec 20 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$303.00K$224.00K$4.91M-----
Avg Forecast$301.50K$1.35M$4.66M$6.36M$4.80M$16.86M$31.09M$73.91M
High Forecast$354.92K$1.50M$5.00M$6.69M$5.15M$18.08M$33.34M$79.25M
Low Forecast$232.32K$1.17M$4.32M$6.01M$4.44M$15.62M$28.79M$68.44M
Surprise %0.50%-83.40%5.36%-----

Net Income Forecast

$-90M $-71M $-52M $-33M $-14M $5M Dec 20 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-9.35M$-20.84M$-13.32M$-12.98M----
Avg Forecast$-70.04M$-34.75M$-13.32M$-6.07M$-4.67M$-4.99M$-3.20M$1.06M
High Forecast$-49.15M$-28.89M$-13.15M$-5.49M$-4.53M$-2.27M$-199.80K$1.16M
Low Forecast$-86.18M$-39.79M$-15.92M$-6.65M$-4.80M$-7.72M$-6.19M$955.63K
Surprise %-86.65%-40.03%-113.79%----

PSTV Forecast FAQ

Is Plus Therapeutics stock a buy?

Plus Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Plus Therapeutics is a favorable investment for most analysts.

What is Plus Therapeutics's price target?

Plus Therapeutics's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $0.35.

How does Plus Therapeutics stock forecast compare to its benchmarks?

Plus Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Plus Therapeutics over the past three months?

  • June 2025: 50.00% Strong Buy, 25.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Plus Therapeutics’s EPS forecast?

Plus Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.49, marking a 645.00% increase from the reported $-0.2 in 2024. Estimates for the following years are $-1.51 in 2026, $-1.08 in 2027, and $0.34 in 2028.

What is Plus Therapeutics’s revenue forecast?

Plus Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $4.8M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $16.86M, followed by $31.09M for 2027, and $73.91M for 2028.

What is Plus Therapeutics’s net income forecast?

Plus Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-4.665M, representing a -64.05% decrease from the reported $-12.978M in 2024. Projections indicate $-4.991M in 2026, $-3.197M in 2027, and $1.06M in 2028.